BRAND NAME / COMPANY /
REIMBURSEMENT AND LOGISTICS PROGRAM (APPROVED BY HEALTH CANADA FOR IBD INDICATIONS)
Tremfya®/Johnson & Johnson Innovative Medicine/BioAdvance® (CD UC 2025)
CLASS
Monoclonal antibody interleukin (IL)-23 inhibitor
ACTION
Targets IL-23 protein receptor, which is one of the proteins responsible for inflammation. Blocking this receptor contributes to reducing inflammation.
